Clinical Trials
3 trialsNCT01649271 2025-02-11
Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer.
Boehringer Ingelheim
Phase 1 Completed
NCT00950742 2025-02-10
Phase I Open Label Trial to Assess Safety of BIBW 2992 (Afatinib) in Combination With HerceptinĀ® in Patients With HER2-positive Advanced Breast Cancer.
Boehringer Ingelheim
Phase 1 Completed
NCT03878524 2024-03-04
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Phase 1 Terminated